

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/037,036	10/25/2001	Jonathan S. Stinson	S639919	5380	
490	7590 10/11/2006	10/11/2006		EXAMINER	
VIDAS, ARRETT & STEINKRAUS, P.A. 6109 BLUE CIRCLE DRIVE SUITE 2000			NGUYEN, VI X		
			ART UNIT	PAPER NUMBER	
MINNETON	MINNETONKA, MN 55343-9185				
			DATE MAILED: 10/11/2000	6	

Please find below and/or attached an Office communication concerning this application or proceeding.

#### **DETAILED ACTION**

#### Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-24 are rejected under 35 U.S.C. 102 (b) as being anticipated by Healy (5,670,161).

Healy discloses in fig 5, a process for forming a stent having the limitations of claims 1-23, including: the process comprises the step of forming a tubular stent of the polymer material (see col.9, lines 22-46); the stent radially expanding to produce an expanded diameter stent, annealing the expanded diameter stent (see col. 10, lines 49-65) that shrinks (see col. 7, lines 50-57) from its expanded diameter to a reduced diameter, and at least one time repeating of steps b) and c) in sequence.

Regarding claims 3 and 23, Healy discloses the stent is formed by molding or etching the polymer material (see col.9, lines17-21).

Regarding claims 4-5, Healy discloses the polymer material is thermoplastic or biodegradable (see col.3, lines 31-34).

Regarding claims 6-7 and 19, Healy discloses the polymer material is selected from the group consisting of PLA (poly(alpha-hydroxy acid) which is selected from the group consisting of PLA (polyglycolide) (see col.10, lines 35-49).

Art Unit: 3734

Regarding claims 8-9, Healy discloses the process has a temperature that is below the glass transition temperature of the polymer material; and wherein the step b) performs at room temperature (see col.3, lines 38-45, lines 54-59 and col.4, lines 57-65).

Regarding claims 10-11, Healy discloses the process has a temperature that is above the glass transition temperature of the polymer material; and wherein the step c) performs at a temperature about 130 degree Celsius (see col.10, lines 1-9).

Regarding claims 12-14 are a product-by-process claim, and according to MPEP § 2113, these claims are not limited to the manipulations of the recited steps, only the structure implied by the steps. The patentability of a product does not depend on its method of production, but on the product itself. Therefore, how the stent is being manufactured is not further limiting the estructure of the claimed stent.

Regarding claims 16-20 and 24, Healy discloses a medical device adapted for body lumen navigation (see col. 3, lines 31-60) and a pattern of perforation is seen an a tube wall (see col. 4, lines 36-50.

### Allowable Subject Matter

2. Claim 25 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The following is a statement of reasons for the indication of allowable subject matter:

None of the prior art of record disclose or suggest where the steps a-c are all performed prior to deployment of a stent in a body.

Art Unit: 3734

As allowable subject matter has been indicated, applicant's reply must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP § 707.07(a).

## Response to Arguments

3. Applicant's arguments see pages 7-8, filed 8/1/2006 have been fully considered but they are not persuasive.

In response to applicant's argument that the Healy reference does not disclose an expanding stent has an expanded diameter stent, and annealing the expanded diameter stent to shrink its diameter to a reduced diameter: As claims 1, 15 and 21 are currently written, they can be interpreted broadly that the Healy reference at least discloses in fig.5, the expanding stent (see col. 3, lines 39-44 and col. 11, lines 40-44) has an expanded diameter stent, and annealing(see col. 10, lines 49-65) the expanded diameter stent to shrink (col. 7, lines 50-57) its diameter to a reduced diameter. Accordingly, the above noted reference is still considered to read on the claimed limitations of the claims noted.

#### Conclusion

4. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 10/037,036

Art Unit: 3734

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Victor X. Nguyen whose telephone number is (571) 272-4699. The examiner can normally be reached on M-F (8-4.30 P.M).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hayes can be reached on (571) 272-4697. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Victor X Nguyen Victor

Page 5

Art Unit 3734

VN 9/30/2006

MICHAEL J. HAYES
SUPERVISORY PATENT EXAMINER